Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.
Ibandronate Versus Placebo as add-on to Active Vitamin D and Calcium in the Prevention of Bone Loss After Renal Transplantation.
Sponsor: Oslo University Hospital
This PHASE2/PHASE3 trial investigates Renal Transplant and is currently ongoing. Oslo University Hospital leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oslo University Hospital
- Smerud Medical Research International AS
For direct contact, visit the study record on ClinicalTrials.gov .